近日，據(jù)英國《每日郵報(bào)》報(bào)道,，一組來自瑞士,、法國、巴西和美國的科學(xué)家在《英國癌癥雜志》British Journal of Cancer 發(fā)表論文“Cancer cell proliferation is inhibited by specific modulation frequencies,，”文中稱,，低頻電磁場在治療癌變腫瘤方面有著驚人的效果。這一研究成果或許能把癌癥從不治之癥的名單上抹掉,。
在這項(xiàng)研究過程中,，參與臨床試驗(yàn)的病人口中含著一個(gè)調(diào)羹狀的天線，天線隨之把電磁場傳入病患體內(nèi),。經(jīng)過3周的治療后,，一小部分病人的情況明顯改善——腫瘤體積或者縮小，或者不再增大,；與此同時(shí),，癌變組織周圍的健康細(xì)胞也未受到影響。
研究發(fā)現(xiàn),，頻率在0.1赫茲到114千赫的低頻電磁場能夠抑制一小部分患者體內(nèi)惡性腫瘤的生長,。據(jù)悉，不同癌癥對應(yīng)著不同的頻率,。不過,，科學(xué)家們表示，此項(xiàng)研究仍處于初級階段,，他們將在未來幾年中進(jìn)行進(jìn)一步研究,。
對此，參與這項(xiàng)研究的亞拉巴馬大學(xué)伯明翰分校的鮑里斯·帕斯教授指出,，這種治療方式能夠長期進(jìn)行,，并且可以與其他治療方式搭配使用。目前,，帕斯教授已經(jīng)獲得美國食品藥品監(jiān)督管理局的批準(zhǔn),，能夠?qū)Υ罅堪┌Y患者進(jìn)行臨床試驗(yàn)。同時(shí),，為了籌措下一步研究經(jīng)費(fèi),，他還在其他國家來回奔走。
《英國癌癥雜志》的報(bào)道中并沒有對低頻電磁場能夠治療癌癥的具體原理予以說明,。不過,，低頻電磁場能夠治療癌癥的研究結(jié)果同目前存在的一些說法相矛盾——即手機(jī)和輸電塔等電子技術(shù)能夠引發(fā)癌癥和白血病。對此,，帕斯堅(jiān)稱他在試驗(yàn)中使用的電磁場頻率比手機(jī)釋放出的電磁頻率低100到1000倍,。
英國癌癥研究中心的埃莉諾·巴里對這項(xiàng)研究結(jié)果表示歡迎,。她在接受采訪時(shí)說：“這項(xiàng)研究表明，在實(shí)驗(yàn)室中,，特定頻率的低頻電磁場在減緩癌癥發(fā)展方面是有效的,。目前我們?nèi)晕床槊靼┘?xì)胞對低頻電磁場做出此種反應(yīng)的原因所在，也不清楚這種方法是否能夠?qū)Σ』加兴鶐椭?。不過,，這是研究人員努力嘗試開發(fā)新辦法、在抑制癌細(xì)胞的同時(shí)又不使健康細(xì)胞受損的一個(gè)生動例子,。”（生物谷Bioon.com）
doi:10.1038/bjc.2011.523
PMC:
PMID:
Cancer cell proliferation is inhibited by specific modulation frequencies
J W Zimmerman, M J Pennison, I Brezovich, N Yi, C T Yang, R Ramaker, D Absher, R M Myers, N Kuster, F P Costa, A Barbault and B Pasche
Background: There is clinical evidence that very low and safe levels of amplitude-modulated electromagnetic fields administered via an intrabuccal spoon-shaped probe may elicit therapeutic responses in patients with cancer. However, there is no known mechanism explaining the anti-proliferative effect of very low intensity electromagnetic fields. Methods: To understand the mechanism of this novel approach, hepatocellular carcinoma (HCC) cells were exposed to 27.12 MHz radiofrequency electromagnetic fields using in vitro exposure systems designed to replicate in vivo conditions. Cancer cells were exposed to tumour-specific modulation frequencies, previously identified by biofeedback methods in patients with a diagnosis of cancer. Control modulation frequencies consisted of randomly chosen modulation frequencies within the same 100 Hz–21 kHz range as cancer-specific frequencies. Results: The growth of HCC and breast cancer cells was significantly decreased by HCC-specific and breast cancer-specific modulation frequencies, respectively. However, the same frequencies did not affect proliferation of nonmalignant hepatocytes or breast epithelial cells. Inhibition of HCC cell proliferation was associated with downregulation of XCL2 and PLP2. Furthermore, HCC-specific modulation frequencies disrupted the mitotic spindle. Conclusion: These findings uncover a novel mechanism controlling the growth of cancer cells at specific modulation frequencies without affecting normal tissues, which may have broad implications in oncology
